Microencapsulation of apomorphine HCl with gelatin

International Journal of Pharmaceutics

Volumn 148, Issue 1, 1997, Pages 23-32

  Ugwoke, Michael Ikechukwu ^a   Verbeke, Nobert ^a   Kinget, Renaat ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Apomorphine HCl; Controlled release; Gelatin microsphere; Microencapsulation; Nasal drug delivery; Riboflavin sodium phosphate

Indexed keywords

APOMORPHINE; GELATIN; MICROSPHERE;

ARTICLE; CONTROLLED RELEASE FORMULATION; CROSS LINKING; DRUG RELEASE; EMULSION; MICROENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL;

EID: 0031001898     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(96)04819-3     Document Type: Article

References (26)

1. Corboy, D.L., Wagner, M.L. and Sage, J.I., Apomorphine for motor fluctuation and freezing in Parkinson's disease. Neurology, 29 (1995) 282-288.
2. Corsini, G.U., Gessa, G.L., Del Zompo, M. and Mangoni, A., Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet, i (1979) 954-956.
3. Gancher, S.T., Nutt, J.G. and Woodward, W.R., Absorption of apomorphine by various route in Parkinsonism. Movement disorders, 6 (1991) 212-216.
4. Kapoor, R., Turjanski, N. and Frankel, J.P., Intranasal apomorphine: a new treatment in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr., 53 (1991) 1015.
5. Leucuta, S.E., The kinetics of in vitro release and the pharmacokinetics of miotic response in rabbits of gelatin and albumin microspheres with pilocarpine. Int. J. Pharm., 54 (1989) 71-78.
6. Longer, M.A. and Robinson, J.R., Fundamental aspects of bioadhesion. Pharm. Int., 7 (1986) 114-117.
7. Luzzi, L.A. and Gerraughty, R.J., Effect of additives and formulation techniques on controlled release of drugs from microcapsules. J. Pharm. Sci., 9 (1967) 1174-1177.
8. Mortazavi, S.A. and Smart, J.D., An investigation into the role of water movement and mucus gel dehydration in mucoadhesion. J. Controlled Release, 25 (1993) 197-203.
9. Nastruzzi, C., Pastesini, C., Cortesi, R., Esposito, E., Gambari, R. and Menegatti, E., Production and in vitro evaluation of gelatin microspheres containing an antitumour tetra-amidine. J. Microencap., 11 (1994) 249-260.
10. Obeso, J.A., Grandas, F. and Luquin, M.R., Apomorphine infusion for motor fluctuations in Parkinson's disease. Lancet, i (1987) 1376-1377.
11. Poewe, W., Kleedorfer, B., Gerstebrand, F. and Oerterl, W., Subcutaneous apomorphine in Parkinson's disease. Lancet, i (1988) 943.
12. Pollak, P., Champay, A.S., Hommel, M., Perret, J.E. and Benabid, A.L., Subcutaneous apomorphine in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 52 (1989) 544.
13. Raymond, G., Degennaro, M. and Mikeal, R., Preparation of gelatin:phenytoin sodium microspheres: an in vitro and in vivo evaluation. Drug Dev. Ind. Pharm., 16 (1990) 1025-1051.
14. Ritger, P.L. and Peppas, N.A., A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Controlled Release, 5 (1987) 23-36.
15. Sam, E., Augustijns, P. and Verbeke, N., Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. J. Chromatogr., B658 (1994) 311-317.
16. Sam, E., Jeanjean, A.P., Maloteaux, J.M. and Verbeke, N., Apomorphine pharmacokinetics after intranasal and subcutaneous application. Eur. J. Drug Metab. Pharmacokinet., 20 (1995) 27-33.
17. Stibe, C., Lees, A. and Stern, G., Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet, i (1987) 871.
18. Stibe, C.M., Kempster, P.A., Lees, A.J. and Stern, G.M., Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet, i (1988) 403-406.
19. Tanaka, N., Takino, S. and Utsumi, I., A new oral gelatinized sustained-release dosage form. J. Pharm. Sci., 52 (1963) 664-667.
20. Ugwoke, M.I. and Kinget, R., Submitted for publication. J. Microencap., 1996.
21. van Laar, E., Jansen, E.N.H., Essink, A.W.G. and Neef, C., Intranasal apomorphine in parkinsonian on-off fluctuations. Arch. Neurol., 49 (1992a) 482-484.
22. van Laar, E., Jansen, E.N.H., Essink, A.W.G., Rutten, W.J. and Neef, C., Rectal apomorphine: a new treatment in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr., 55 (1992b) 737-738.
23. Vandelli, M.A., Forni, F., Iannuccelli, V. and Cameroni, R.J., The concentration of the crosslinking agent as a tool for the control of release and swelling properties of gelatin microspheres. Pharm. Belg., 46 (1991a) 381-388.
24. Vandelli, M.A., Forni, F., Coppi, G. and Cameroni, R., The effect of the crosslinking time period upon the drug release and dynamic swelling of gelatin microspheres. Pharmazie, 46 (1991b) 866-869.
25. Vyas, S.P., Bhatnagar, S., Goigoi, P.J. and Jain, N.K., Preparation and characterization of HSA-propranolol microspheres for nasal administration. Int. J. Pharm., 69 (1991) 5-12.
26. Wan, L.S.C., Heng, P.W.S. and Chan, L.W., Drug encapsulation in alginate microspheres by emulsification. J. Microencap., 9 (1992) 309-316.